Quantum BioPharma Ltd. (QNTM)
| Market Cap | 7.20M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.47M |
| Shares Out | 1.30M |
| EPS (ttm) | -12.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,920 |
| Open | 3.860 |
| Previous Close | 3.800 |
| Day's Range | 3.630 - 3.865 |
| 52-Week Range | 3.500 - 97.500 |
| Beta | 0.85 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 23, 2024 |
About QNTM
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism o... [Read more]
News
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US
TORONTO, ON / ACCESSWIRE / September 25, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company...
Quantum BioPharma Closes Private Placement Offering
Toronto, Ontario--(Newsfile Corp. - September 13, 2024) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K9) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to ...
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
TORONTO, ON / ACCESSWIRE / September 9, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a port...
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements
TORONTO, ON / ACCESSWIRE / September 6, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company ...
Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can "own NOW and what's NEXT"
TORONTO, ON / ACCESSWIRE / August 30, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfo...
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update
TORONTO, ON / ACCESSWIRE / August 23, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company de...
FSD Pharma Announces Share Consolidation and Name Change
Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfol...
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team
TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its investment in Celly Nutrition Corp. ("Celly Nu"), a privately he...
24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD Pharma
Denver, Colorado--(Newsfile Corp. - July 25, 2024) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news ...
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - July 23, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfol...
24/7 Market News Publishes Report Covering Biotech Developments, Featuring FSD Pharma
Denver, Colorado--(Newsfile Corp. - July 23, 2024) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news ...
FSD Pharma Files Amended and Restated Material Change Report
Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfoli...
FSD Pharma provides Corporate Update
TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovativ...
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biot...
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
TORONTO, ON / ACCESSWIRE / June 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biot...
FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications
TORONTO, ON / ACCESSWIRE / June 13, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biot...
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
TORONTO, ON / ACCESSWIRE / June 4, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biote...
FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest
TORONTO, ON / ACCESSWIRE / May 31, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biote...
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
TORONTO, ON / ACCESSWIRE / May 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), it...
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
TORONTO, ON / ACCESSWIRE / May 7, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative ...
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
TORONTO, ON / ACCESSWIRE / April 30, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" of the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovati...
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM)
TORONTO, ON / ACCESSWIRE / April 25, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), ...
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
TORONTO, ON / ACCESSWIRE / April 22, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), ...
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
TORONTO, ON / ACCESSWIRE / April 17, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovati...
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
TORONTO, ON / ACCESSWIRE / April 15, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its investment in Celly Nutrition Corp. ("Celly Nu"), a privately he...